Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

In contrast, oncogenic 'driver' mutations such as BCR-ABL are important ... Identification of molecular pathways that drive BRCA1 or BRCA2 deficiency–associated cancers will probably be ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

A Mayo Clinic-led team of researchers is solving one of the most frustrating aspects of genetic cancer screening — results that give zero guidance to patients on whether they are at elevated risk.

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

In the 1990s, scientists at The Institute of Cancer Research identified the breast cancer 2 gene, BRCA2, and mutations in it that greatly increase the carrier’s risk of developing breast cancer and ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying ...

Followed categories will be added to My News. She has one of the most commonly inherited gene mutations – BRCA2 – which increases the risk of breast, ovarian and prostate cancers. Mia tested ...

having one or both mutations increases potential risk significantly. Around 50 out of 100 women with either a BRCA1 or BRCA2 gene mutations will get breast cancer by the time they are 70 ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...